Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis
- 2 May 2019
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 66 (8) , e27790
Abstract
Background: Kaposiform lymphangiomatosis (KLA) is a rare lymphatic anomaly with significant morbidity and mortality. KLA is characterized by diffuse multifocal lesions comprised of focal areas of “kaposiform” spindled cells accompanying malformed lymphatic channels. The goal of this study was to identify activated signaling pathways in cells isolated from three KLA patients for the purpose of testing new therapies.Procedure: Cells were obtained from the lungs of one patient isolated at autopsy and the spleen of two patients removed in surgery due to disease complications. A protein kinase array was performed on the KLA cell lysates and normal lymphatic endothelial cells.Results: Higher activation of key signaling pathways in the KLA cells, including PRAS40, AKT1/2/3, and ERK‐1/2, was identified by protein kinase array and confirmed by Western blot analysis. This indicated a role for highly activated PI3K–AKT and MAPK–ERK‐1/2 signaling pathways in KLA cells. Cell proliferation studies assessed PI3K inhibitors (LY294002; BYL719), AKT inhibitor ARQ092, mTOR inhibitor rapamycin, and MAPK inhibitor U0126. These studies demonstrated that PI3K–AKT–mTOR and MAPK signaling are important mediators of KLA cell proliferation. BYL719 and rapamycin were more effective at inhibiting KLA cell proliferation than U0126.Conclusions: Our studies using cells from KLA patient lesions demonstrate that these cells are highly proliferative and the PI3K–AKT–mTOR and MAPK pathways are promising therapeutic targets. Development and clinical trials of PI3K, AKT, and MAPK inhibitors for cancer treatment and the data in this study lend support for early clinical trials assessing the efficacy of these inhibitors in KLA patients.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (R01 HL117952)
- National Institutes of Health
This publication has 24 references indexed in Scilit:
- Targeted therapy in patients with PIK3CA-related overgrowth syndromeNature, 2018
- Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human StudyJournal of Clinical Oncology, 2018
- In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)neurogenetics, 2018
- PRAS40 signaling in tumorOncotarget, 2017
- Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategiesAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2016
- Sirolimus in the Treatment of Vascular AnomaliesEuropean Journal of Pediatric Surgery, 2016
- Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT InhibitorJournal of Medicinal Chemistry, 2016
- Lymphatic and Other Vascular Malformative/Overgrowth Disorders Are Caused by Somatic Mutations in PIK3CAThe Journal of Pediatrics, 2015
- Successful treatment of kaposiform lymphangiomatosis with sirolimusPediatric Blood & Cancer, 2015
- Kaposiform lymphangiomatosis: Unifying features of a heterogeneous disorderPediatric Blood & Cancer, 2014